A health check pilot for heartburn and Barrett’s oesophagus patients will be expanded to more pharmacies in north central London, C+D can exclusively reveal.
Diagnostics company Cyted Health, which is running the pilot testing for oesophageal cancer, confirmed it is planning a further expansion to pharmacies in Barnet, Haringey and Islington in January 2027.
Currently, 21 pharmacies in those areas are taking part - including a Boots branch - along with six pharmacies in the East Midlands.
Read more: Boots to pilot pharmacy ‘sponge on a string’ cancer test
And C+D can reveal that 268 patients have been tested so far across the whole pilot, which was announced in July 2025.
The pilot hopes to reach 1,360 patients and is due to stop recruiting new pharmacies by June 30, 2027.
The final evaluation report will then be completed by December 31, 2027, Cyted Health told C+D.
Read more: ‘Heartburn test’ for cancer launches in East Midlands
C+D reported in August that across five East Midlands pharmacies, 79 patients had been tested and 25 of them had been referred on for further care.
A sixth participating pharmacy in the East Midlands – a Boots branch in Newark – joined the pilot on November 6.
In north central London, a Wood Green Boots pharmacy and seven community pharmacies joined the pilot in July, while another 13 joined last month.
‘Sponge on a string’ test
The health check pilot is a test for heartburn and Barrett’s oesophagus patients using the “minimally-invasive” EndoSign capsule sponge test that collects cells from your oesophagus without going through an endoscopy.
As part of the NHS Cancer Programme, the pilot is aimed at people over the age of 45 experiencing persistent heartburn or acid reflux.
The NHS introduced the pilot because it wanted to make testing “more convenient” outside of hospitals and introduce it to community settings such as pharmacies and community diagnostic centres.
Read more: Pharmacies will play increased role in new UK cancer plan
Known as a “sponge on a string” test, it can be delivered in under 10 minutes, as the patient swallows a small pill on a thread that expands into a sponge on reaching the stomach.
The sponge is safely pulled out collecting cells from the oesophagus lining and is tested to detect “early biological changes” associated with Barrett’s oesophagus and oesophageal cancer.
If pre-cancerous cells are found, treatment can be offered to remove the cells through an endoscopy or radiofrequency ablation.
Read more: Ulcers an ‘important opportunity’ for pharmacies to flag cancer risk
It comes as the National Institute for Health and Care Excellence (NICE) today published draft guidance recommending EndoSign as one of the tests to help detect oesophageal cancer and Barrett’s oesophagus.
If the NICE recommendations are confirmed - with the final guidance due in February 2027 - the NHS in England “will be required to begin delivery of the technology within the clinical pathway”, and this will include specialist staff training across the country.
And it follows the government announcing its new National Cancer Plan in February, which involves the launch of “heartburn tests”.

